AVADEL PHARMACEUTICALS PLC 4

Insider Amin Naseem tendered 22,000 Avadel ordinary shares and had options on 71,500 shares cashed out for $21.00 per share (plus CVRs) in connection with Alkermes’ acquisition of Avadel.

On February 12, 2026, in connection with Alkermes plc’s acquisition of Avadel Pharmaceuticals plc via an Irish scheme of arrangement, reporting person Amin Naseem disposed of 22,000 Avadel ordinary shares for $21.00 per share in cash plus a contingent value right (CVR) of up to $1.50 per share, and all of his outstanding stock options were canceled and converted into cash-and-CVR consideration. Specifically, options covering 49,500 shares at a $15.94 strike (expiring May 17, 2034), 11,000 shares at a $16.32 strike (expiring July 30, 2034), and 11,000 shares at a $10.83 strike (expiring July 29, 2035) were cashed out for the intrinsic value based on the $21.00 deal price plus one CVR per underlying share. These dispositions include previously restricted stock awards that fully vested at closing and were treated as common in the merger; following the transaction, Naseem no longer holds Avadel equity, as the issuer became a wholly owned subsidiary of Alkermes.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014438

Alert Tier

6